Management of toxicities of immune checkpoint inhibitors

Cancer Treatment Reviews

Volumn 44, Issue , 2016, Pages 51-60

  Spain, Lavinia ^a   Diem, Stefan ^a   Larkin, James ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Immune checkpoint inhibitors; Immune related adverse events; Ipilimumab; Lung cancer; Melanoma; Nivolumab; Pembrolizumab; Renal cancer

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNE CHECKPOINT INHIBITOR; IMMUNOSUPPRESSIVE AGENT; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; PREDNISOLONE; STEROID; UNCLASSIFIED DRUG; CORTICOSTEROID; CYCLOSPORIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INFLIXIMAB; LYMPHOCYTE ANTIBODY; MONOCLONAL ANTIBODY; MYCOPHENOLATE MOFETIL; MYCOPHENOLIC ACID; PROGRAMMED DEATH 1 RECEPTOR; TACROLIMUS;

ADVANCED CANCER; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL (TOPIC); COLITIS; CONJUNCTIVITIS; DIABETES MELLITUS; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ENDOCRINE DISEASE; ENDOCRINE OPHTHALMOPATHY; ENTEROCOLITIS; EYE TOXICITY; FATIGUE; GASTRITIS; GASTROINTESTINAL SYMPTOM; HEPATITIS; HUMAN; HYPERTENSION; HYPERTHYROIDISM; HYPOPHYSITIS; HYPOTHYROIDISM; IMMUNE RESPONSE; INSOMNIA; IRITIS; KIDNEY CANCER; KIDNEY INJURY; LUNG CANCER; LYMPHOMA; MELANOMA; MESOTHELIOMA; MOOD DISORDER; MYALGIA; MYOSITIS; NEPHRITIS; NEUROLOGIC DISEASE; NEUTROPENIA; OPPORTUNISTIC INFECTION; OSTEOPOROSIS; PATIENT CARE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PRURITUS; RASH; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SKIN TOXICITY; THROMBOCYTOPENIA; THYROID DISEASE; TREATMENT INDICATION; UVEITIS; VITILIGO; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CARCINOMA, RENAL CELL; CHEMICALLY INDUCED; DRUG ERUPTIONS; DRUG-INDUCED LIVER INJURY; KIDNEY NEOPLASMS; LUNG NEOPLASMS; NEOPLASMS; PITUITARY DISEASES; SKIN NEOPLASMS; THYROIDITIS;

ADRENAL CORTEX HORMONES; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTILYMPHOCYTE SERUM; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; COLITIS; CTLA-4 ANTIGEN; CYCLOSPORINE; DIARRHEA; DRUG ERUPTIONS; DRUG-INDUCED LIVER INJURY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLIXIMAB; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MELANOMA; MYCOPHENOLIC ACID; NEOPLASMS; PITUITARY DISEASES; PROGRAMMED CELL DEATH 1 RECEPTOR; SKIN NEOPLASMS; TACROLIMUS; THYROIDITIS;

EID: 84975728236     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2016.02.001     Document Type: Review

References (91)

1. Curran M.A., Montalvo W., Yagita H., Allison J.P. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA 2010, 107:4275-4280.
2. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723.
3. Kwon E.D., Drake C.G., Scher H.I., Fizazi K., Bossi A., van den Eertwegh A.J., et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 2014, 15:700-712.
4. Eggermont A.M., Chiarion-Sileni V., Grob J.J., Dummer R., Wolchok J.D., Schmidt H., et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol 2015, 16:522-530.
5. Robert C., Schachter J., Long G.V., Arance A., Grob J.J., Mortier L., et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015, 372:2521-2532.
6. Robert C., Thomas L., Bondarenko I., O'Day S., Weber J., Garbe C., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011, 364:2517-2526.
7. Robert C., Long G.V., Brady B., Dutriaux C., Maio M., Mortier L., et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015, 372:320-330.
8. Weber J.S., D'Angelo S.P., Minor D., Hodi F.S., Gutzmer R., Neyns B., et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015, 16:375-384.
9. Ribas A., Puzanov I., Dummer R., Schadendorf D., Hamid O., Robert C., et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 2015, 16:908-918.
10. Larkin J., Chiarion-Sileni V., Gonzalez R., Grob J.J., Cowey C.L., Lao C.D., et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015, 373:23-34.
11. Brahmer J.R., Tykodi S.S., Chow L.Q., Hwu W.J., Topalian S.L., Hwu P., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012, 366:2455-2465.
12. Wolchok J.D., Neyns B., Linette G., Negrier S., Lutzky J., Thomas L., et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010, 11:155-164.
13. Robert C., Ribas A., Wolchok J.D., Hodi F.S., Hamid O., Kefford R., et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014, 384:1109-1117.
14. Rizvi N.A., Mazieres J., Planchard D., Stinchcombe T.E., Dy G.K., Antonia S.J., et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol 2015, 16:257-265.
15. Gettinger S.N., Horn L., Gandhi L., Spigel D.R., Antonia S.J., Rizvi N.A., et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2015, 33:2004-2012.
16. Brahmer J., Reckamp K.L., Baas P., Crino L., Eberhardt W.E., Poddubskaya E., et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015, 373:123-135.
17. Herbst R.S., Baas P., Kim D.W., Felip E., Perez-Gracia J.L., Han J.Y., et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2015, 373:1627-1639.
18. Borghaei H., Paz-Ares L., Horn L., Spigel D.R., Steins M., Ready N.E., et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015, 373:1627-1639.
19. Garon E.B., Rizvi N.A., Hui R., Leighl N., Balmanoukian A.S., Eder J.P., et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015, 372:2018-2028.
20. Calabro L., Morra A., Fonsatti E., Cutaia O., Amato G., Giannarelli D., et al. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. Lancet Oncol 2013, 14:1104-1111.
21. Calabro L., Morra A., Fonsatti E., Cutaia O., Fazio C., Annesi D., et al. Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study. Lancet Respir Med 2015, 3:301-309.
22. Motzer R.J., Rini B.I., McDermott D.F., Redman B.G., Kuzel T.M., Harrison M.R., et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol 2015, 33:1430-1437.
23. Motzer R.J., Escudier B., McDermott D.F., George S., Hammers H.J., Srinivas S., et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015, 373:1803-1813.
24. Ansell S.M., Lesokhin A.M., Borrello I., Halwani A., Scott E.C., Gutierrez M., et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015, 372:311-319.
25. Westin J.R., Chu F., Zhang M., Fayad L.E., Kwak L.W., Fowler N., et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol 2014, 15:69-77.
26. Armand P., Nagler A., Weller E.A., Devine S.M., Avigan D.E., Chen Y.B., et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J Clin Oncol 2013, 31:4199-4206.
27. Le D.T., Uram J.N., Wang H., Bartlett B.R., Kemberling H., Eyring A.D., et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015, 372:2509-2520.
28. Weber J.S., Kahler K.C., Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012, 30:2691-2697.
29. Ibrahim R, Berman DM, DePril V, Humphrey RW, Chen T, Messina M, et al. Ipilimumab safety profile: Summary of findings from completed trials in advanced melanoma. American Society Clinical Oncology (ASCO); J Clin Oncol, (Suppl.; abstr 8583), Chicago, 2011.
30. Weber J, Antonia S, Topalian SL, Schadendorf D, Larkin J, Sznol M, et al. Safety profile of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL): a pooled analysis. American Society Clinical Oncology (ASCO); J Clin Oncol 33, (Suppl.; abstr 9018), Chicago, 2015.
31. Ryder M., Callahan M., Postow M.A., Wolchok J., Fagin J.A. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer 2014, 21:371-381.
32. Johnson D.B., Friedman D.L., Berry E., Decker I., Ye F., Zhao S., et al. Survivorship in immune therapy: assessing chronic immune toxicities, health outcomes, and functional status among long-term ipilimumab survivors at a single referral center. Cancer Immunol Res 2015, 3:464-469.
33. U.S.D.o.H.a.H. Services. Common Terminology Criteria for Adverse Events; Version 4.0; 2009. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference:8.5x11.pdf.
34. Chmiel K.D., Suan D., Liddle C., Nankivell B., Ibrahim R., Bautista C., et al. Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy. J Clin Oncol 2011, 29:e237-e240.
35. Venditti O., De Lisi D., Caricato M., Caputo D., Capolupo G.T., Taffon C., et al. Ipilimumab and immune-mediated adverse events: a case report of anti-CTLA4 induced ileitis. BMC Cancer 2015, 15:87.
36. Gentile N.M., D'Souza A., Fujii L.L., Wu T.T., Murray J.A. Association between ipilimumab and celiac disease. Mayo Clin Proc 2013, 88:414-417.
37. Bristol Myers Squibb. Yervoy (Ipilimumab) Product Information; 2015. http://packageinserts.bms.com/pi/pi_yervoy.pdf.
38. Merck Sharp & Dohme Corp. Keytruda (Pembrolizumab) Product Information; 2015. http://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf.
39. Kim K.W., Ramaiya N.H., Krajewski K.M., Shinagare A.B., Howard S.A., Jagannathan J.P., et al. Ipilimumab-associated colitis: CT findings. AJR Am J Roentgenol 2013, 200:W468-W474.
40. Berman D., Parker S.M., Siegel J., Chasalow S.D., Weber J., Galbraith S., et al. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immun 2010, 10:11.
41. Robinson M.R., Chan C.C., Yang J.C., Rubin B.I., Gracia G.J., Sen H.N., et al. Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis. J Immunother 2004, 27:478-479.
42. Bristol Myers Squibb. Opdivo (Nivolumab) Product Information; 2015. http://packageinserts.bms.com/pi/pi_opdivo.pdf.
43. Bhatia S., Huber B.R., Upton M.P., Thompson J.A. Inflammatory enteric neuropathy with severe constipation after ipilimumab treatment for melanoma: a case report. J Immunother 2009, 32:203-205.
44. Ludlow S.P., Kay N. Delayed dermatologic hypersensitivity reaction secondary to ipilimumab. J Immunother 2015, 38:165-166.
45. Minkis K., Garden B.C., Wu S., Pulitzer M.P., Lacouture M.E. The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta-analysis. J Am Acad Dermatol 2013, 69:e121-e128.
46. Klein O., Ebert L.M., Nicholaou T., Browning J., Russell S.E., Zuber M., et al. Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4. Clin Cancer Res 2009, 15:2507-2513.
47. Pavlick A, Ott PA, Kannan R, Madden KM, Sorlie C, Escano C, et al. Hair depigmentation as an indicator of durable response to CTLA-4 therapy. American Society Clinical Oncology (ASCO); J Clin Oncol, (Suppl.; abstr 8571), Chicago, 2010.
48. Hua C., Boussemart L., Mateus C., Routier E., Boutros C., Cazenave H., et al. Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol 2016, 152:45-51.
49. Voskens C.J., Goldinger S.M., Loquai C., Robert C., Kaehler K.C., Berking C., et al. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS ONE 2013, 8:e53745.
50. Kyllo R.L., Parker M.K., Rosman I., Musiek A.C. Ipilimumab-associated Sweet syndrome in a patient with high-risk melanoma. J Am Acad Dermatol 2014, 70:e85-e86.
51. Gormley R., Wanat K., Elenitsas R., Giles J., McGettigan S., Schuchter L., et al. Ipilimumab-associated Sweet syndrome in a melanoma patient. J Am Acad Dermatol 2014, 71:e211-e213.
52. Attia P., Phan G.Q., Maker A.V., Robinson M.R., Quezado M.M., Yang J.C., et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005, 23:6043-6053.
53. Weber J, Gibney G, Yu B, Cheng P, Martinez A, Kroeger J, et al. Survival, biomarker, and toxicity analysis of nivolumab (NIVO) in patients that progressed on ipilimumab (IPI). American Society Clinical Oncology (ASCO); J Clin Oncol 33, (Suppl.; abstr 9055), Chicago, 2015.
54. Corsello S.M., Barnabei A., Marchetti P., De Vecchis L., Salvatori R., Torino F. Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab 2013, 98:1361-1375.
55. Torino F., Barnabei A., Paragliola R.M., Marchetti P., Salvatori R., Corsello S.M. Endocrine side-effects of anti-cancer drugs: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses. Eur J Endocrinol 2013, 169:R153-R164.
56. Albarel F., Gaudy C., Castinetti F., Carre T., Morange I., Conte-Devolx B., et al. Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma. Eur J Endocrinol 2015, 172:195-204.
57. Dillard T., Yedinak C.G., Alumkal J., Fleseriu M. Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes. Pituitary 2010, 13:29-38.
58. Martin-Liberal J., Furness A.J., Joshi K., Peggs K.S., Quezada S.A., Larkin J. Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report. Cancer Immunol Immunother 2015, 64:765-767.
59. Fadel F., El Karoui K., Knebelmann B. Anti-CTLA4 antibody-induced lupus nephritis. N Engl J Med 2009, 361:211-212.
60. Gaudy-Marqueste C., Monestier S., Franques J., Cantais E., Richard M.A., Grob J.J. A severe case of ipilimumab-induced guillain-barre syndrome revealed by an occlusive enteric neuropathy: a differential diagnosis for ipilimumab-induced colitis. J Immunother 2013, 36:77-78.
61. Maur M., Tomasello C., Frassoldati A., Dieci M.V., Barbieri E., Conte P. Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma. J Clin Oncol 2012, 30:e76-e78.
62. Manousakis G., Koch J., Sommerville R.B., El-Dokla A., Harms M.B., Al-Lozi M.T., et al. Multifocal radiculoneuropathy during ipilimumab treatment of melanoma. Muscle Nerve 2013, 48:440-444.
63. Mandel J.J., Olar A., Aldape K.D., Tremont-Lukats I.W. Lambrolizumab induced central nervous system (CNS) toxicity. J Neurol Sci 2014, 344:229-231.
64. Chan M.M., Kefford R.F., Carlino M., Clements A., Manolios N. Arthritis and tenosynovitis associated with the anti-PD1 antibody pembrolizumab in metastatic melanoma. J Immunother 2015, 38:37-39.
65. Goldstein B.L., Gedmintas L., Todd D.J. Drug-associated polymyalgia rheumatica/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of ctla-4. Arthritis Rheumatol 2014, 66:768-769.
66. Geisler B.P., Raad R.A., Esaian D., Sharon E., Schwartz D.R. Apical ballooning and cardiomyopathy in a melanoma patient treated with ipilimumab: a case of takotsubo-like syndrome. J Immunother Cancer 2015, 3:4.
67. Laubli H., Balmelli C., Bossard M., Pfister O., Glatz K., Zippelius A. Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. J Immunother Cancer 2015, 3:11.
68. Simeone E., Grimaldi A.M., Esposito A., Curvietto M., Palla M., Paone M., et al. Serious haematological toxicity during and after ipilimumab treatment: a case series. J Med Case Rep 2014, 8:240.
69. Delyon J., Mateus C., Lambert T. Hemophilia A induced by ipilimumab. N Engl J Med 2011, 365:1747-1748.
70. Vogel W.V., Guislain A., Kvistborg P., Schumacher T.N., Haanen J.B., Blank C.U. Ipilimumab-induced sarcoidosis in a patient with metastatic melanoma undergoing complete remission. J Clin Oncol 2012, 30:ee7-ee10.
71. Tissot C., Carsin A., Freymond N., Pacheco Y., Devouassoux G. Sarcoidosis complicating anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody biotherapy. Eur Respir J 2013, 41:246-247.
72. Reule R.B., North J.P. Cutaneous and pulmonary sarcoidosis-like reaction associated with ipilimumab. J Am Acad Dermatol 2013, 69:e272-e273.
73. Murphy K.P., Kennedy M.P., Barry J.E., O'Regan K.N., Power D.G. New-onset mediastinal and central nervous system sarcoidosis in a patient with metastatic melanoma undergoing CTLA4 monoclonal antibody treatment. Oncol Res Treat 2014, 37:351-353.
74. Eckert A., Schoeffler A., Dalle S., Phan A., Kiakouama L., Thomas L. Anti-CTLA4 monoclonal antibody induced sarcoidosis in a metastatic melanoma patient. Dermatology 2009, 218:69-70.
75. Berthod G., Lazor R., Letovanec I., Romano E., Noirez L., Mazza Stalder J., et al. Pulmonary sarcoid-like granulomatosis induced by ipilimumab. J Clin Oncol 2012, 30:e156-159.
76. Andersen R., Norgaard P., Al-Jailawi M.K., Svane I.M. Late development of splenic sarcoidosis-like lesions in a patient with metastatic melanoma and long-lasting clinical response to ipilimumab. Oncoimmunology 2014, 3:e954506.
77. Heffernan M.P., Saag K.G., Robinson J.K., Callen J.P. Prevention of osteoporosis associated with chronic glucocorticoid therapy. JAMA 2006, 295:1300-1303.
78. Topalian S.L., Sznol M., McDermott D.F., Kluger H.M., Carvajal R.D., Sharfman W.H., et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014, 32:1020-1030.
79. Yousaf N., Davidson M., Goode E., Thomas C., Hung R., Gore M., et al. The cost of ipilimumab toxicity: a single-centre analysis. Melanoma Res 2015, 25:259-264.
80. Yang J.C., Hughes M., Kammula U., Royal R., Sherry R.M., Topalian S.L., et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 2007, 30:825-830.
81. Downey S.G., Klapper J.A., Smith F.O., Yang J.C., Sherry R.M., Royal R.E., et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 2007, 13:6681-6688.
82. Amin A, DePril V, Hamid O, Wolchok J, Maio M, Neyns B, et al. Evaluation of the effect of systemic corticosteroids for the treatment of immune-related adverse events (irAEs) on the development or maintenance of ipilimumab clinical activity. American Society Clinical Oncology (ASCO); J Clin Oncol, (Suppl.; abstr 9037), Chicago, 2009.
83. Horvat T.Z., Adel N.G., Dang T.O., Momtaz P., Postow M.A., Callahan M.K., et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial sloan kettering cancer center. J Clin Oncol 2015, 33:3193-3198.
84. Danlos F.X., Pages C., Roux J., Jebali M., Gornet J.M., Bagot M., et al. Atypical severe immune-related adverse effects resulting from sequenced immunotherapy in melanoma. Melanoma Res 2015, 25:178-179.
85. Chiarion-Sileni V., Pigozzo J., Ascierto P.A., Simeone E., Maio M., Calabro L., et al. Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy. Br J Cancer 2014, 110:1721-1726.
86. Lebbe C., Weber J.S., Maio M., Neyns B., Harmankaya K., Hamid O., et al. Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies. Ann Oncol 2014, 25:2277-2284.
87. Krammer R., Heinzerling L. Therapy preferences in melanoma treatment-willingness to pay and preference of quality versus length of life of patients, physicians and healthy controls. PLoS ONE 2014, 9:e111237.
88. Lipson E.J., Bodell M.A., Kraus E.S., Sharfman W.H. Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma. J Clin Oncol 2014, 32:e69-e71.
89. Bostwick A.D., Salama A.K., Hanks B.A. Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis. J Immunother Cancer 2015, 3:19.
90. Kyi C., Carvajal R.D., Wolchok J.D., Postow M.A. Ipilimumab in patients with melanoma and autoimmune disease. J Immunother Cancer 2014, 2:35.
91. Johnson DB, Khushalani NI, Puzanov I, Mudigonda T, Kaufman H, Sosman JA, et al. Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders. American Society Clinical Oncology (ASCO); J Clin Oncol 33, (Suppl.; abstr 9019), Chicago, 2015.